Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SH) announced that its subsidiary, Zhejiang Hisun Animal Health Products Co., Ltd., recently received approval from the Ministry of Agriculture and Rural Affairs of China for two veterinary drug products: Compound Nystatin Ointment and Toltrazuril Suspension.
The approval of these products will further enrich the company's veterinary drug portfolio and enhance its product structure. This development aligns with Zhejiang Hisun Pharmaceutical's strategic expansion in the veterinary drug sector and strengthens its market competitiveness.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments